Heart failure (HF) is a serious public health issue because its prevalence is increasing in epidemic proportions as a result of higher average age of population survival and population growth. Consequently, early diagnosis, prevention measures and better treatments (both medical and surgical) are actively sought after.
This project aims to develop point-of-care devices for the early diagnosis of heart failure (HF). Electrochemical biosensors including field effect transistors, microfluidics and flexible electronic devices will be developed and integrated for the in-vitro diagnostic of existing (BNP) and novel (sAXL) cardiac markers will be developed.
The developments planned in the project nanocardioflex implement innovative platforms based on competitive biosensing for sensitive and selective determination of receptor tyrosine kinase AXL. These platforms will meet the requirements of miniaturization, ease of use and allow management the possibility of decentralized analysis required for the development of POC devices. This development will take place thanks to the multidisciplinary approach provided by the consortium members, and will integrate the new solution proposed in this project.Brio Apps AlphaSIP
, an Aragonese company, leads the project, in which the Complutense University of Madrid
, the National Microelectronics Centre (Barcelona) and Hospital Clínic of Barcelona
are the key partners. This consortium gratefully acknowledges funding from the Spanish Ministry of Economy, the Spanish Department of Industry, and the European Commission.